Department of Gastroenterology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China.
Department of Gastroenterology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China.
J Pain. 2024 Nov;25(11):104616. doi: 10.1016/j.jpain.2024.104616. Epub 2024 Jun 25.
Centrally mediated abdominal pain syndrome (CAPS) has generated a heavy disease burden worldwide. This study aimed to explore the serum exosomal microRNAs (miRNAs) as potential diagnostic biomarkers for CAPS. From September 2022 to October 2023, 97 patients with CAPS and 96 healthy subjects were enrolled. Differentially expressed serum exosomal miRNAs between patients with CAPS and healthy controls were identified by high-throughput sequencing and quantitative real-time polymerase chain reaction. The receiver operating characteristic curves and multivariate logistic regression analysis were used to evaluate the diagnostic value of the serum exosomal miRNAs. MiR-6850-5p, miR-194-5p, miR-199a-3p, and miR-4525 were significantly downregulated in serum exomes of CAPS patients compared with healthy controls, which yielded the area under curve (AUC) values of .914 (95% confidence interval (CI), .873-.954), .767 (95% CI, .695-.839), .617 (95% CI, .527-.708), and .561 (95% CI, .465-.656), respectively, to distinguish CAPS patients from healthy subjects. And AUC of the integration of the above 4 miRNAs was .931 (95% CI, .896-.966). Multivariate logistic regression indicated that hsa-miR-6850-5p (odds ratio (OR) = .046, P < .001), anxiety (OR = 7.670, P = .025), and depression (OR = 22.967, P = .008) were the independent predictors of CAPS. Serum exosomal miR-6850-5p is a promising diagnostic biomarker for CAPS. PERSPECTIVE: This study may be the first to explore serum exosomal miRNAs as new diagnostic biomarkers for CAPS, and the findings may help clinicians to access comprehensive understanding and accurate diagnosis of CAPS.
中枢介导的腹痛综合征 (CAPS) 在全球范围内造成了沉重的疾病负担。本研究旨在探讨血清外泌体 microRNAs (miRNAs) 是否可作为 CAPS 的潜在诊断生物标志物。本研究纳入了 2022 年 9 月至 2023 年 10 月期间的 97 例 CAPS 患者和 96 例健康对照者。通过高通量测序和实时定量聚合酶链反应鉴定 CAPS 患者和健康对照者血清外泌体 miRNAs 的差异表达。采用受试者工作特征曲线和多变量逻辑回归分析评估血清外泌体 miRNAs 的诊断价值。与健康对照组相比，CAPS 患者血清外泌体中 miR-6850-5p、miR-194-5p、miR-199a-3p 和 miR-4525 显著下调，曲线下面积 (AUC) 值分别为.914 (95%置信区间 (CI)，.873-.954)、.767 (95% CI，.695-.839)、.617 (95% CI，.527-.708) 和.561 (95% CI，.465-.656)，可区分 CAPS 患者与健康对照者。上述 4 种 miRNA 整合的 AUC 为.931 (95% CI，.896-.966)。多变量逻辑回归表明，hsa-miR-6850-5p (比值比 (OR) =.046，P <.001)、焦虑 (OR = 7.670，P =.025) 和抑郁 (OR = 22.967，P =.008) 是 CAPS 的独立预测因子。血清外泌体 miR-6850-5p 是 CAPS 的一种有前途的诊断生物标志物。展望：本研究可能首次探索血清外泌体 miRNAs 是否可作为 CAPS 的新型诊断生物标志物，研究结果可能有助于临床医生全面了解并准确诊断 CAPS。
